Trimetazidine pills 35mg №60

Composition

1 pill contains the active substance: Trimetazidine dihydrochloride - 35 mg;

Pharmacotherapeutic group

Antihypoxic drug

Mechanism of action

It has an antihypoxic effect.
Directly affecting the cardiomyocytes and neurons of the brain, the drug optimizes their metabolism and function. The cytoprotective effect is due to increased energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased glycolysis and blockade of fatty acid oxidation).
Trimetazidine maintains myocardial contractility, prevents the decrease in the intracellular content of adenosine triphosphate (ATP) and phosphocreatine. Under conditions of acidosis, it normalizes the functioning of the ion channels of the membrane, prevents the accumulation of Calcium and sodium ions in cardiomyocytes, and normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and elevated phosphate levels due to myocardial ischemia and reperfusion. Interferes with the damaging effects of free radicals, preserves the integrity of cell membranes, prevents activation of neutrophils in the ischemic area, increases the duration of electrical potential, reduces the release of creatine phosphokinase (CPK) from cells and the severity of ischemic myocardial damage.
Trimetazidine reduces the frequency of strokes, reduces the need for taking nitrates, after 2 weeks of intake increases exercise tolerance, reduced sharp fluctuations in blood pressure (BP).

Indications for use

Ischemic heart disease: prevention of attacks of stable angina (as part of complex therapy).

Contraindications

• hypersensitivity to any component of the drug;

• severe renal failure (creatinine clearance (CC) less than 30 ml / min);
• age up to 18 years (efficacy and safety not established);
• pregnancy and breastfeeding;

• Parkinson's disease, symptoms of parkinsonism, tremor, restless legs syndrome and other related motor disorders.

Dosage and Administration

The drug should be taken orally, during the meal.
Trimetazidine MB is prescribed 1 pill 2 times a day (in the morning and in the evening). In patients with moderate renal impairment (creatinine clearance from 30 to 60 ml / min), the drug is prescribed 1 pill per day during breakfast. In elderly patients, trimetazidine exposure may be increased due to age-related impairment of renal function. It is recommended to take 1 pill 1 time per day. The advantage of therapy should be evaluated after 3 months, in the absence of effect, therapy should be discontinued.